Bodei L - Search Results

1

¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Among authors: bodei l. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.

2

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF. Ricci S, et al. Among authors: bodei l. Ann Oncol. 2000 Sep;11(9):1127-30. doi: 10.1023/a:1008383132024. Ann Oncol. 2000. PMID: 11061606 Free article. Clinical Trial.

3

In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas.

Bodei L, Hofland LJ, Ferone D, Mooy CM, Kros JM, Paridaens DA, Baarsma SG, Ferdeghini M, Van Hagen MP, Krenning EP, Kwekkeboom DJ. Bodei L, et al. Cancer Biother Radiopharm. 2003 Dec;18(6):895-902. doi: 10.1089/108497803322702860. Cancer Biother Radiopharm. 2003. PMID: 14969602

4

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46. doi: 10.1007/s00259-004-1571-4. Epub 2004 May 19. Eur J Nucl Med Mol Imaging. 2004. PMID: 15150675 Review.

5

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP. Kwekkeboom DJ, et al. Among authors: bodei l. J Nucl Med. 2005 Jan;46 Suppl 1:62S-6S. J Nucl Med. 2005. PMID: 15653653 Free article. Review.

6

Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.

Sierra ML, Agazzi A, Bodei L, Pacifici M, Aricò D, De Cicco C, Quarna J, Sansovini M, De Simone M, Paganelli G. Sierra ML, et al. Among authors: bodei l. Cancer Biother Radiopharm. 2009 Dec;24(6):659-65. doi: 10.1089/cbr.2009.0641. Cancer Biother Radiopharm. 2009. PMID: 20025545

7

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35. doi: 10.1007/s00259-011-1902-1. Epub 2011 Sep 3. Eur J Nucl Med Mol Imaging. 2011. PMID: 21892623 Clinical Trial.

8

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6. Eur J Nucl Med Mol Imaging. 2013. PMID: 23389427 Free PMC article.

9

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, Scarpi E, Matteucci F, Gilardi L, Paganelli G. Severi S, et al. Among authors: bodei l. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):881-8. doi: 10.1007/s00259-013-2369-z. Epub 2013 Feb 27. Eur J Nucl Med Mol Imaging. 2013. PMID: 23443937

10

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19. doi: 10.1007/s00259-014-2893-5. Epub 2014 Oct 2. Eur J Nucl Med Mol Imaging. 2015. PMID: 25273832 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page